Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mannan-binding lectin (MBL) production from human plasma.

I Laursen1

  • 1Department of Research and Development, Division of Plasma Products, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen, Denmark. inl@ssi.dk

Biochemical Society Transactions
|July 31, 2003
PubMed
Summary

Mannan-binding lectin (MBL) deficiency increases infection risk. Plasma-derived MBL shows promise as a safe and effective substitution therapy for MBL-deficient individuals, restoring immune function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mannan-binding lectin and healing of a radiation-induced chronic ulcer--a case report on mannan-binding lectin replacement therapy.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2011
Same author

Comparison of rocket and crossed immuno-electrophoresis assays for determination of the level of actin complexing of Gc globulin.

Scandinavian journal of clinical and laboratory investigation·2007
Same author

Second-generation nanofiltered plasma-derived mannan-binding lectin product: process and characteristics.

Vox sanguinis·2007
Same author

Interaction of C1q with the receptor calreticulin requires a conformational change in C1q.

Scandinavian journal of immunology·2004
Same author

Gc globulin (vitamin D-binding protein) levels: an inhibition ELISA assay for determination of the total concentration of Gc globulin in plasma and serum.

Scandinavian journal of clinical and laboratory investigation·2004
Same author

Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study.

Scandinavian journal of immunology·2004

Area of Science:

  • Immunology
  • Biochemistry
  • Therapeutic Protein Development

Background:

  • Low mannan-binding lectin (MBL) levels are linked to increased susceptibility to infectious diseases.
  • Mannan-binding lectin (MBL) substitution therapy is a potential treatment for MBL deficiency.

Purpose of the Study:

  • To develop a production process for plasma-derived MBL.
  • To evaluate the safety and tolerability of this MBL product in MBL-deficient individuals.

Main Methods:

  • Plasma fractionation using ethanol precipitation.
  • Affinity chromatography on a cross-linked agarose matrix for MBL isolation.
  • Safety and tolerability assessment in adult volunteers.

Main Results:

Related Experiment Videos

  • A production process yielding approximately 25% of plasma MBL content with 65% purity was established.
  • The MBL product demonstrated mannan-binding activity and complement-activating ability.
  • Plasma-derived MBL was found to be safe and well-tolerated in MBL-deficient volunteers.

    • Conclusions:

    • A viable method for producing MBL from human plasma has been developed.
    • Plasma-derived MBL is a safe and potentially effective therapeutic option for MBL deficiency.
    • Further clinical evaluation is warranted to confirm therapeutic efficacy.